Understanding Your Pathology Report

A pathology report is a medical report that describes the characteristics of a tissue or blood specimen that has been removed from your body. The specimen is analyzed by a pathologist, who writes a report of their findings for the doctor who has ordered the report and/or performed the procedure.

Jun 17, 2024

bluehq

Understanding Your Biomarker Test Report

You had probably never even heard of biomarkers until you faced a cancer diagnosis, but they're a very important part of treatment planning. Since every tumor has its own unique pattern of biomarkers, knowing your biomarker profile can help you and your doctor choose the right treatment for your specific tumor.

Jun 17, 2024

bluehq

Hepatic Artery Infusion (HAI) Therapy for Colorectal Cancer with Tumors in the Liver (Mets)

If you have colorectal cancer that has spread to the liver, you may want to consider Hepatic Artery Infusion (HAI) therapy. HAI therapy is an FDA-approved cancer treatment that delivers a concentrated dose of medicine into the liver through the hepatic artery. Unlike systemic chemotherapy, HAI therapy is delivered only to the tumor site in the liver, so it does not add additional systemic side effects to the rest of the body.

Feb 28, 2025

bluehq

HAI liver pump for mCRC offers second chances

Hope Brooks is the vision of health. She exercises daily, teaches core power yoga, keeps up with doctor appointments, and participates in other healthy habits. Weeks after her 50th birthday, Hope began to experience abdominal pain, which led to a trip to urgent care. A simple blood draw prompted concern for her liver.

Feb 28, 2025

bluehq

BRAF Biomarker

The BRAF gene is present in all the cells in our bodies. A BRAF mutation (a change or damage to the gene) is found in about 10% of colorectal cancer patients. If your biomarker tests show an abnormal BRAF mutation, treatments that target abnormal BRAF genes may be helpful. BRAF inhibitors are drugs that can turn off and stop mutated BRAF activity.

Apr 1, 2025

bluehq

KRAS Biomarker

KRAS biomarkers are members of the RAS family of genes that include NRAS and HRAS. A normal KRAS gene teams up with a group of proteins as an “on/off” switch to monitor cell growth. An abnormal mutation in the KRAS gene happens early in the development of cancer. Approximately 40-45% of colorectal cancer patients have a KRAS mutation in their tumor. Patients with mutated or unknown KRAS status should receive chemotherapy including FOLFOX, CAPOX, or FOLFIRI with or without bevacizumab.

Apr 1, 2025